BMY

$48.50

▲+0.41%

wb_incandescent Backtest

Stock

Bristol-Myers Squibb Company Common Stock

Official Company Name: Bristol-Myers Squibb Company

Stock Symbol: BMY

Stock Market: New York Stock Exchange - NYSE

Currency: United States dollar - USD

business Bristol Myers Squibb Company Profile

BMY Stock Price - 1 Year Price Evolution & Moving Averages

1 Year Return

▼-30.25%

file_download

Daily closing prices, with moving averages and volumes - United States dollar (USD)
Moving averages:

  • EMA20
  • SMA50
  • SMA200

Company Description

Bristol Myers Squibb Company, also known as BMS, is a multinational pharmaceutical company. Tracing its origins to1858, it develops and manufactures prescription pharmaceuticals and biologics for a diverse range of diseases including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders.

business Bristol Myers Squibb Company Profile

BMY Stock Data

Open $48.26
High $48.57
Low $48.15
Close $48.50
Volume 1,031,360
Previous Close $48.30
1-Day Change 0.20
1-Year Change -21.03
Average Daily Volume 12,604,844
52-Week High $70.54
52-Week Low $47.84

BMY Stock References

warning

Disclaimer

All information and data available on Disfold is NOT FINANCIAL ADVICE. Invest at your own risk!

Past performance is not a guarantee of future performance. Patterns tend to repeat themselves, but they don't necessarily have to.

Successful backtests on past data do not guarantee the future success of the strategy backtested, especially as backtest overfitting may occur: when the price of a stock may fit particularly well a given trading strategy over a given period, but not necessarily outside of that period. Besides, backtests do not account for exact market conditions and may yield significantly different results in real trading practice (fees, slippage...).

Furthermore, even though Disfold strives to provide the best and most accurate data, errors can occur in Disfold's systems, or in our data providers' systems.

Please conduct your own due diligence to verify insights.